Adjuvant treatment with pembrolizumab continued to induce a disease-free survival benefit vs placebo in patients with resected early-stage NSCLC, according to findings from the phase 3 PEARLS/KEYNOTE-091 trial.
Data from several recent phase 3 trials support changes to standard care for NSCLC, according to researchers. Data from several recent phase 3 trials support changes to standard care for NSCLC, according to researchers.
Data from three trials with the amivantamab in advanced EGFR-mutant NSCLC have yielded "exciting" results with experts hailing the drug as standard of care in various settings.